Category: Uncategorized

Research Triangle Park, NC, November 13, 2024 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in the 15th Annual Craig-Hallum Alpha Select Conference. The Company’s management will be available for one-on-one meetings throughout the event. Conference Details: Event: 15th Annual Craig-Hallum Alpha Select ConferenceDate: […]

Read More… from FENNEC PHARMACEUTICALS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCE

~ Achieved Third Quarter 2024 Net Product Sales of $7.0 Million ~ ~ Increasing Momentum and Successful Reimbursement in the Adolescent and Young Adult (AYA) Segment Following Strategic Investments to Drive Awareness of Ototoxicity & Adoption of PEDMARKÒ ~ ~ Strengthened Executive Leadership Team with Chief Medical Officer, Chief Commercial Officer & Chief Strategy Officer […]

Read More… from FENNEC PHARMACEUTICALS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

RESEARCH TRIANGLE PARK, N.C., October 31, 2024 – Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its third quarter 2024 financial results before the opening of the U.S. financial markets on Thursday, November 7, 2024. Management will host a conference call and webcast that […]

Read More… from Fennec Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024

~ Pierre S. Sayad, PhD, M.S., Appointed Chief Medical Officer ~ ~ Terry Evans Appointed Chief Commercial Officer ~ ~ Christiana Cioffi, MBA, Appointed Chief Strategy Officer ~ RESEARCH TRIANGLE PARK, N.C., October 28, 2024 – Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that it has strengthened its […]

Read More… from Fennec Pharmaceuticals Strengthens Executive Leadership Team with Three Key Appointments to Accelerate the Company’s Next Stage of Growth

September 05, 2024 RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2024 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in upcoming investor conferences. The management team will also host one-on-one investor meetings at the conferences. Conference Details: Event: H.C. Wainwright Global Investment ConferenceDate: September 11, 2024Time: Company Presentation […]

Read More… from FENNEC PHAMACEUTICALS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

~ Achieved Second Quarter 2024 Total Net Revenues of $7.3 Million ~ ~ Appointed Jeffrey S. Hackman as Chief Executive Officer (CEO) and Member of the Board of Directors ~ ~ Company Has Approximately $43 Million in Cash, Cash Equivalents, and Investment Securities ~ ~ Management to Host Conference Call Today at 8:30 a.m. ET ~ Research […]

Read More… from FENNEC PHARMACEUTICALS REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

~ Company to Also Participate in 2024 Wedbush PacGrow Healthcare Conference ~ RESEARCH TRIANGLE PARK, N.C., August 6, 2024 – Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its second quarter 2024 financial results and provide a business update before the opening of the […]

Read More… from FENNEC PHARMACEUTICALS TO REPORT SECOND QUARTER 2024 FINANCIAL RESULTS ON AUGUST 13, 2024

~ Accomplished Industry Leader Brings Extensive Commercialization and Oncology Expertise ~ ~ Assumes Leadership Role at Critical Time to Expand Use of PEDMARK®, the First and Only Approved Treatment to Reduce the Risk of Cisplatin-Induced Ototoxicity ~ RESEARCH TRIANGLE PARK, N.C., August 5, 2024 – Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty […]

Read More… from FENNEC PHARMACEUTICALS APPOINTS JEFFREY S. HACKMAN AS CHIEF EXECUTIVE OFFICER AND DIRECTOR  

RESEARCH TRIANGLE PARK, N.C., July 1, 2024 – Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that Adrian Haigh has departed from his position as Fennec’s Chief Operating Officer as of June 30, 2024. After nine years as an independent director, in August 2023, Adrian joined the Fennec leadership […]

Read More… from FENNEC PHARMACEUTICALS ANNOUNCES MANAGEMENT CHANGE

Research Triangle Park, NC — (Marketwired) –June 25, 2024 – Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 29, 2024 (the “Circular”) for the Annual General Meeting of Shareholders were elected as directors of the Company at the Annual General Meeting of Shareholders […]

Read More… from FENNEC ANNOUNCES RESULTS OF ANNUAL MEETING